Jump to content

Resigratinib

From Wikipedia, the free encyclopedia
Resigratinib
Identifiers
CAS Number
PubChem CID
Chemical and physical data
FormulaC26H27F2N7O3
Molar mass523.545 g·mol−1
3D model (JSmol)
  • CNC1=C(C(=NN1[C@H]2C[C@@H](N(C2)C(=O)C=C)COC)C#CC3=C(C=C4C(=C3F)N=CN4C5CC5)F)C(=O)N
  • InChI=1S/C26H27F2N7O3/c1-4-21(36)33-11-15(9-16(33)12-38-3)35-26(30-2)22(25(29)37)19(32-35)8-7-17-18(27)10-20-24(23(17)28)31-13-34(20)14-5-6-14/h4,10,13-16,30H,1,5-6,9,11-12H2,2-3H3,(H2,29,37)/t15-,16+/m0/s1
  • Key:YXVDEILMUVTDMK-JKSUJKDBSA-N

Resigratinib (KIN-3248) is an experimental anticancer medication which acts as a fibroblast growth factor receptor inhibitor (FGFRi) and is in early stage human clinical trials.[1][2][3]

See also

[edit]

References

[edit]
  1. ^ Franovic A, Mohan A, Uryu S, Wu Q, Jiang P, Miller N, et al. (February 2022). "Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations". Journal of Clinical Oncology. 40 (4_suppl): 461. doi:10.1200/JCO.2022.40.4_suppl.461.
  2. ^ Harding JJ, Perez CA, Kato S, Sharma M, Garmezy B, Quah CS, et al. (February 2023). "First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations". Journal of Clinical Oncology. 41 (4_suppl): TPS637-TPS637. doi:10.1200/JCO.2023.41.4_suppl.TPS637. S2CID 256257314.
  3. ^ Wang Z, Anderson KS (2022). "Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer". Cancer Journal (Sudbury, Mass.). 28 (5): 354–362. doi:10.1097/PPO.0000000000000615. PMC 9523489. PMID 36165723.